Research programme: therapeutic antibodies - ESBATech
Alternative Names: ESBA212; ESBA521; ESBA903Latest Information Update: 24 Jun 2011
Price :
$50 *
At a glance
- Originator ESBATech
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease; Cancer; Inflammation
Most Recent Events
- 19 May 2005 Preclinical trials in Alzheimer's disease in Switzerland (unspecified route)
- 01 Apr 2004 Preclinical trials in Inflammation in Switzerland (unspecified route)
- 01 Apr 2004 Preclinical trials in Cancer in Switzerland (unspecified route)